Categories
Change Password!
Reset Password!
Intermittent PTH 1–34 administration was found to increase the
circulating mesenchymal
stem cell density in women with
postmenopausal osteoporosis.
As per the findings of a study published in the
peer-reviewed general medical journal, intermittent parathyroid hormone (PTH)
exerts an anabolic role in bone formation and therefore, can potentially for
tissue regeneration and stem cell transplantation therapy, especially among
women suffering from Postmenopausal Osteoporosis. Before this analysis, the
role of PTH in stimulating osteogenesis and improving bone marrow mesenchymal stem
cell (MSC) density was known but on circulating MSCs was unexplained. This
analysis focused on to find the impact of intermittent PTH 1–34 and alendronate
administration (12 months) on circulating MSCs in the peripheral blood of 54
postmenopausal osteoporotic females who were at high risk of fracture.
The collection of whole blood samples was done at baseline,
one, three, six, and twelve months following the introduction of medications.
Identification of circulating MSCs was made using the flow cytometry analyses.
Circulating MSCs were separated from peripheral blood and cultured in
osteogenic medium to explore the osteogenic differentiation potential. Serum
markers of bone mineral density (BMD), bone formation, and bone resorption were
estimated.
By one month, Teriparatide treatment increased circulating
MSCs, which persisted until month 12. This rise in circulating MSCs showed a
positive correlation with improvements in spine BMD (at month 12), bone
formation and bone resorption biomarkers (at month 6). Evident from enhanced
ALP-expressing cell density, Runx-2, OSX, COL 1a1, calcium deposition, alkaline
phosphatase (ALP) activity, and osteocalcin mRNA upregulation, intermittent PTH
1–34 administration known to improved in vitro osteogenic differentiation of
circulating MSCs. These outcomes revealed that intermittent PTH 1–34
administration helps to increase the circulating MSC density in women with
postmenopausal osteoporosis.
Med Sci Monit
Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women.
Yutao Tang et al.
Comments (0)